Health Sovereignty: EUROAPI Supports the Supply of Essential Medicines to France and Europe
June 13 2023 - 7:55AM
Business Wire
- Increased production capacity of opioid pain relievers by 2027
through innovative processes
- Antibiotic production re-launch project and securing
anti-inflammatory manufacturing to meet public health needs as part
of the Important Project of Common European Interest (IPCEI)
Regulatory News:
EUROAPI (Paris:EAPI) is further addressing health sovereignty
concerns in France and Europe. The Group is announcing several
initiatives to increase its production capacities for several
active pharmaceutical ingredients listed as essential medicines by
the French authorities.
EUROAPI’s Francopia1 subsidiary dedicated to controlled
substances2, will invest in R&D activities on its Vertolaye
(Puy-de-Dôme) site. These R&D activities aim to increase
EUROAPI’s production of morphine and its derivatives, as well as
their antagonists used as antidotes, by 2027.
- At the plant extraction stage, the Group aims to develop an
innovative process that could increase productivity between 20% and
30% and shortening industrial cycle time to help building up
strategic stocks. This innovative process would also improve
solvent recycling and save energy.
- At the chemical synthesis stage, EUROAPI plans to invest in
more flexible technologies and equipment that would enhance
production capacity by 15% to 20%.
"EUROAPI projects are emblematic of what we are striving for
when it comes to health sovereignty: increase our production
capacity or relocate medicines that are essential for the health of
the French people, building on the development of innovative
production processes that are more competitive and environmentally
friendly. These projects are part of the eight new relocation
projects announced today in Ardèche by the President of the
Republic, which will allow us to significantly reduce our
dependence on non-European imports on a number of drugs over the
next five years,” said Mr. Roland Lescure, Minister Delegate in
charge of Industry.
"EUROAPI is proud to address health sovereignty challenges
identified by the French Government and to fight drug shortages",
said Karl Rotthier, Chief Executive Officer of EUROAPI. "Innovation
will enable us to increase our production in order to ensure the
sustainable, competitive and integrated manufacturing of
pharmaceutical intermediates and active ingredients in Europe, such
as anti-inflammatory drugs and antibiotics, all essential to public
health."
Once the R&D projects have been successfully completed,
EUROAPI plans further investments to increase its production
capacity. Total investments could reach €70 million, of which
approximately 15% in R&D and 85% in capex, that would be
deployed from 2026. These investments will be partially funded by
the French State via France 2030.
In addition, as part of the Important Project of Common European
Interest (IPCEI) currently under review by the European Commission,
EUROAPI has presented innovative projects to help cover the need
for currently imported critical medicines such as macrolide
antibiotics and corticosteroids, by 2030.
- For corticosteroids (including methylprednisolone) used for
their anti-inflammatory and immunosuppressive effects, EUROAPI’s
ambition is to develop state-of-the-art processes and technologies
at the Vertolaye site.
- With regard to the macrolide antibiotics used to treat
infectious diseases, the project to relaunch production would be
deployed at the Saint-Aubin-lès-Elbeuf (Seine-Maritime) site and
would enable EUROAPI to expand its portfolio in this global
market.
About EUROAPI EUROAPI is focused on reinventing active
ingredient solutions to sustainably meet customers’ and patients’
needs around the world. We are a leading player in active
pharmaceutical ingredients with approximately 200 products in our
portfolio, offering a large span of technologies, while developing
innovative molecules through our Contract Development and
Manufacturing Organization (CDMO) activities.
Taking action for health by enabling access to essential
therapies inspires our 3,450 people every day. With strong research
and development capabilities and six manufacturing sites all
located in Europe, EUROAPI ensures API manufacturing of the highest
quality to supply customers in more than 80 countries. EUROAPI is
listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find
out more at www.euroapi.com and follow us on LinkedIn.
Forward-Looking Statements Certain information contained
in this press release is forward looking and not historical data.
These forward-looking statements are based on opinions, projections
and current assumptions including, but not limited to, assumptions
concerning the Group’s current and future strategy, financial and
non-financial future results and the environment in which the Group
operates, as well as events, operations, future services or product
development and potential. Forward-looking statements are generally
identified by the words “expects”, “anticipates”, “believes”,
“intends”, “estimates”, “plans” and similar expressions. Forward
looking statements and information do not constitute guarantees of
future performances, and are subject to known or unknown risks,
uncertainties and other factors, a large number of which are
difficult to predict and generally outside the control of the
Group, which could cause actual results, performances or
achievements, or the results of the sector or other events, to
differ materially from those described or suggested by these
forward-looking statements. These risks and uncertainties include
those that are indicated and detailed in Chapter 3 “Risk factors”
of the Universal Registration Document approved by the French
Financial Markets Authority (Autorité des marchés financiers, AMF)
on April 14, 2023, under number R.23-009 and the Amendment to
Universal Registration Document approved by the AMF on April 25,
2023 under number R.23-015. These forward-looking statements are
given only as of the date of this press release and the Group
expressly declines any obligation or commitment to publish updates
or corrections of the forward-looking statements included in this
press release in order to reflect any change affecting the
forecasts or events, conditions or circumstances on which these
forward-looking statements are based.
1 Company specializing in controlled substances 100% owned by
EUROAPI 2 Cf EUROAPI’s 2022 Universal Registration Document –
Chapter 3
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230613466829/en/
Media Relations Contact: Laurence Bollack Mob.: +33 (0)6
81 86 80 19 mr@euroapi.com
Investor Relations Contact: Sophie Palliez-Capian Mob.:
+33 (0)6 87 89 33 51 sophie.palliez@euroapi.com
Euroapi (EU:EAPI)
Historical Stock Chart
From May 2024 to Jun 2024
Euroapi (EU:EAPI)
Historical Stock Chart
From Jun 2023 to Jun 2024